SHARE NOW
Oxford Biomedica is exploring the acquisition of ABL Europe in partnership with Institut Mérieux, aiming to provide new opportunities and innovative technologies to ABL Europe while advancing its own position in the cell and gene therapy field. The proposed transaction includes Oxford Biomedica’s acquisition of ABL Europe for $16 million, with Institut Mérieux committing to provide $21 million in additional funding through an equity subscription.
Oxford Biomedica and Institut Mérieux SA have initiated exclusive negotiations for Oxford Biomedica’s potential acquisition of ABL Europe SAS (ABL Europe). This move aligns with Oxford Biomedica’s transformation into a world-leading quality-focused and innovation-led Contract Development and Manufacturing Organization (CDMO) in the cell and gene therapy sector.
Specializing in viral vector development and manufacturing, ABL Europe is a European CDMO with facilities in Lyon and Strasbourg. They focus on delivering Good Manufacturing Practice (GMP)-compliant viral vectors from the early stage to market. ABL Europe plays a crucial role in providing tailored gene and immunotherapy solutions to clients. Their service suite includes bulk drug substance production, precise fill-finish of drug products, robust process and assay development, bioanalytical testing, and comprehensive regulatory guidance.
Dr. Frank Mathias, CEO of Oxford Biomedica, highlighted:
“ABL Europe offers the opportunity to gain a footprint in the EU and free up Oxford Biomedica’s capacity to meet increasing client demand, as well as significantly increasing our capabilities and flexibility for clients.”
How are you enjoying this news article? Let us know your thoughts, here >>
Currently, ABL Europe is involved in over 10 cell and gene therapy programs spanning various disease areas, utilizing more than six different vector types.
The proposed transaction is set to unite Oxford Biomedica and ABL Europe, yielding a multitude of advantages:
- Diversified viral vector portfolio, strengthening Oxford Biomedica’s viral vector offerings
- Augmented capacity to develop and manufacture capacity to address increasing client demands
- Expanding european Customer Base: This move broadens the customer base in Europe, facilitating business growth
- Global footprint expansion of Oxford Biomedica’s international footprint
- Synergies and Revenue Prospects: The combined expertise of both entities could lead to forecasted revenues of approximately €15 million by December 31, 2023.
Furthermore, Institut Mérieux has committed to providing an additional $21 million in funding to ABL Europe through an equity subscription for Oxford Biomedica shares, making Institut Mérieux a major shareholder in Oxford Biomedica.
Michel Baguenault, CEO of Institut Mérieux, stated:
“We are providing ABL Europe’s teams and its French sites with new development prospects and access to innovative technologies, enabling them to expand their offerings to biopharmaceutical companies. As a reference shareholder in Oxford Biomedica, Institut Mérieux intends to support the company’s development in fields that present major challenges for patients, in line with its public health mission.”
Source: Oxford Biomedica Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Discover more like this
